跳至主要内容
临床试验/NCT07072572
NCT07072572已完成3 期

Lung Point Of Care Ultrasond (L-Pocus)-Guided Administration Of Intravenous Albumin In Decompensated Cirrhosis: A Pilot, Open Label, Randomized Controlled Trial

Centro Medico Issemym1 个研究点 分布在 1 个国家目标入组 72 人开始时间: 2023年3月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
72
试验地点
1
主要终点
Overall mortality at 30 days

研究概览

简要总结

To guide the administration of intravenous albumin by lung ultrasound in decompensated cirrhosis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Older than 18 years.
  • Decompensated cirrhosis
  • Indication for intravenous albumin use

排除标准

  • Development of variceal hemorrage before the administration of albumin, respiratory failure previous to albumin use, or the presence of hepatocellular carcinoma

研究组 & 干预措施

Lung ultrasound guided albumin administration group

Experimental

Lung ultrasound guided albumin administration group

干预措施: Lower albumin dosage (Drug)

结局指标

主要结局

Overall mortality at 30 days

时间窗: 30 days

Overall mortality at 30 days

次要结局

  • Acute kidney injury(Every 24 hours, during hospitalization, (assesed up to 28 days))
  • acute-on-chronic liver failure(During hospitailization, (assesed up to 28 days))
  • Resolution of SBP(Day three of antibiotic treatment initiated for spontaneous bacterial peritonitis.)
  • Respiratory failure(Every 24 hours, during hospitalization, (assesed up to 28 days))
  • Development of variceal hemorrhage(During hospitailization, (assesed up to 28 days))
  • Total hospitalization time(30 days)

研究者

发起方
Centro Medico Issemym
申办方类型
Other
责任方
Principal Investigator
主要研究者

Luis Alejandro Rosales Renteria

Principal investigator

Centro Medico Issemym

研究点 (1)

Loading locations...

相似试验